Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
Clinical trial NCT01727336 · TERMINATED
Trial details
- NCT number
- NCT01727336
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-12-01
- Primary completion
- 2017-06-01
- Enrollment
- 160
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.